U.S. Osteonecrosis Market, By Disease Type (Traumatic, Non-Traumatic, and Idiopathic), Type (Diagnosis, and Treatment), Stages (Stage 1, Stage 2, Stage 3, and Stage 4), Location (Osteonecrosis of Hip/Femoral Head Osteonecrosis, Osteonecrosis of the Knee, Osteonecrosis of the Shoulder, Osteonecrosis of the Talus, Osteonecrosis of the Lunate, Osteonecrosis of the Scaphoid, and Others), Drug Type (Branded and Generic), Prescription (Over the Counter Drugs and Prescribed Drugs), Gender (Male and Female), Age (Children, Adult, and Geriatric), End User (Hospitals, Specialty Clinics, Orthopedic Clinics, Ambulatory Centers, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2030.
U.S. Osteonecrosis Market Analysis and Insights
The increasing number of traumatic injuries among the United States population is expected to boost the growth of the U.S. osteonecrosis market. The rising government initiatives and funding for drug discovery and related research programs also contribute to market growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in improved advancement of imaging techniques for the diagnostic purpose of osteonecrosis is also driving the growth of the market in the forecasted period.
The U.S. osteonecrosis market is expected to grow in the forecast year due to the rise in the number of market players and the availability of advanced technological diagnostic and surgical devices. The increasing development in the field of advanced techniques is further expected to boost market growth. However, difficulties such as the stringent regulations for producing and commercializing treatment drugs and medical devices for diagnosis and surgery are expected to restrain market growth in the forecast period.
Various companies are taking initiatives that gradually lead to market growth:
For instance,
- In January 2021, Stryker announced the acquisition of OrthoSensor, a market player which applies digital technology and big data to total joint replacements. The acquisition would help the company to purchase the digital technologies of OrthoSensor for the use in diagnosis and treatment technologies for osteonecrosis.
- In March 2020, Sciegen Pharmaceuticals received ANDA Approval for Naproxen Tablets USP 250mg, 375mg and 500mg. The approval will further help in the growth of the product portfolio of the company.
Data Bridge Market Research analyzes that the U.S. osteonecrosis market is expected to reach the value of USD 843,039.67 thousand by 2030, at a CAGR of 5.9% during the forecast period.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in Thousand, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Traumatic, Non-Traumatic, and Idiopathic), Type (Diagnosis, and Treatment), Stages (Stage 1, Stage 2, Stage 3, and Stage 4), Location (Osteonecrosis of Hip/Femoral Head Osteonecrosis, Osteonecrosis of the Knee, Osteonecrosis of the Shoulder, Osteonecrosis of the Talus, Osteonecrosis of the Lunate, Osteonecrosis of the Scaphoid, and Others), Drug Type (Branded and Generic), Prescription (Over the Counter Drugs and Prescribed Drugs), Gender (Male and Female), Age (Children, Adult, and Geriatric), End User (Hospitals, Specialty Clinics, Orthopedic Clinics, Ambulatory Centers, and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Country Covered
|
U.S.
|
|
Market Players Covered
|
Sciegen Pharmaceuticals, Almatica Pharma, Dr. Reddy's Laboratories Ltd., Bayer AG, Pfizer Inc., Haleon Group of Companies, Zimmer Biomet, Stryker, Teva Pharmaceuticals USA, Inc. (Subsidiary of Teva Pharmaceutical Industries Ltd.), and Arthrex, Inc., among others.
|
U.S. Osteonecrosis Market Definition
Osteonecrosis, also referred to as avascular necrosis or aseptic necrosis, is a condition characterized by the death or deterioration of bone tissue due to an inadequate blood supply. It can occur in various bones in the body, but it most commonly affects the hip joint. The compromised blood flow deprives the bone cells of essential oxygen and nutrients, leading to their death and subsequent damage to the affected bone. As a result, the bone structure weakens, becomes less able to withstand normal stress, and may eventually collapse or become deformed. Osteonecrosis can cause pain, limited range of motion, and functional impairment. Common causes of osteonecrosis include trauma, corticosteroid use, excessive alcohol consumption, certain medical conditions, and underlying factors that affect blood circulation. Early diagnosis and appropriate management are essential in preventing further bone damage and preserving joint function. Treatment options for osteonecrosis may include conservative measures to manage symptoms and slow disease progression and surgical interventions to relieve pain and restore joint function.
U.S. Osteonecrosis Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Driver
- Increasing number of traumatic injuries
The increasing number of traumatic injuries in the U.S. is a significant driver for the U.S. osteonecrosis market. Traumatic injuries, caused by various factors such as accidents, sports-related incidents, falls, and workplace injuries, have become more prevalent in recent years. These injuries can profoundly impact bone health, often resulting in fractures, dislocations, and joint instability. When the blood supply to the affected bone is compromised during the injury, it sets the stage for the potential development of osteonecrosis. The damaged blood vessels disrupt the essential supply of oxygen and nutrients to the bone tissue, leading to the death of bone cells. Post-traumatic osteonecrosis is a well-recognized consequence of severe traumatic injuries. Not promptly diagnosed and managed can lead to complications such as joint collapse, chronic pain, and reduced joint function.
A traumatic injury can damage the blood vessels that deliver oxygen and nutrients to the bone tissue. This disruption leads to a decreased or blocked blood flow, resulting in cellular death and the development of osteonecrosis. Additionally, the trauma can increase pressure on the bone or joint, compromising blood flow and causing ischemia. The resulting lack of blood supply and cellular damage can trigger an inflammatory response, further exacerbating the condition. The increasing number of road and sport-related accidents are increasing, leading to an increase in osteonecrosis.
Restraint
- High cost associated with the diagnosis and treatment of osteonecrosis
The advancements in diagnostic techniques and treatment options have improved patient outcomes. Still, the financial burden of managing osteonecrosis remains a significant challenge for patients, healthcare providers, and the healthcare system. The key factors determining the cost of diagnosis and treatment of osteonecrosis include the medical institution or clinic finalized for the procedure, treatment area, complexity, and chosen specialist among others.
Accurate diagnosis of osteonecrosis often requires specialized imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT) scans, or bone scans. These diagnostic procedures are expensive, requiring specialized equipment, trained personnel, and interpretation by skilled radiologists. The high cost of these imaging procedures limits access to timely and accurate diagnosis, leading to delayed treatment and potential complications. The cost of the treatment proportionally gets escalated, so the high cost of treatment may hamper the market's demand.
Opportunity
-
Advancements in medical technology for osteonecrosis
Advancements in medical technology present significant opportunities in the U.S. osteonecrosis market. These innovations enhance the accuracy of diagnosis, offer regenerative treatment options, enable minimally invasive procedures, facilitate personalized care, and improve patient outcomes. Continued investment in research and development, collaboration between industry and healthcare professionals, and regulatory support for innovative technologies are vital to harness the full potential of medical advancements and drive progress in osteonecrosis. Therefore is expected to act as an opportunity in the market.
Challenge
- Availability of limited treatment options
The absence of therapeutic alternatives in the U.S. osteonecrosis market hampers optimal patient care and outcomes. Osteonecrosis, commonly called avascular necrosis, is a disorder where bone tissue perishes due to inadequate blood flow. Although there are various therapeutic options, the choices are frequently constrained based on osteonecrosis's stage, location, and underlying etiology.
Recent Developments
- In January 2023, Zimmer Biomet announced that it had reached a definitive agreement to acquire Embody, Inc., a privately-held medical device company focused on soft tissue healing, for $155 thousand at closing. The acquisition includes Embody's complete portfolio of collagen-based biointegrative solutions to support healing in the most challenging orthopedic soft tissue injuries – including the TAPESTRY biointegrative implant for tendon healing and TAPESTRY RC, one of the first arthroscopic implant systems for rotator cuff repair. This acquisition will help the company in its product portfolio and business expansion.
- In July 2022, the Haleon Group of Companies announced the completion of the demerger of the Consumer Healthcare business from the GSK Group to form the Haleon Group. This demerges helped the company to take control over the whole business of consumer health and expand it.
U.S. Osteonecrosis Market Scope
The U.S. osteonecrosis market is segmented into ten notable segments based on disease type, type, stages, location, drug type, prescription, gender, age, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Disease Type
- Traumatic
- Non-Traumatic
- Idiopathic
On the basis of disease type, the market is segmented into traumatic, non-traumatic, and idiopathic.
Type
- Diagnosis
- Treatment
On the basis of type, the market is segmented into diagnosis and treatment.
Stages
- Stage 1
- Stage 2
- Stage 3
- Stage 4
On the basis of stages, the market is segmented into stage 1, stage 2, stage3, and stage 4.
Location
- Osteonecrosis of the Hip/ Femoral Head Osteonecrosis
- Osteonecrosis of the Knee
- Osteonecrosis of the Shoulder
- Osteonecrosis of the Talus
- Osteonecrosis of the Lunate
- Osteonecrosis of the Scaphoid
- Others
On the basis of location, the market is segmented into osteonecrosis of hip/femoral head osteonecrosis, osteonecrosis of the knee, osteonecrosis of the shoulder, osteonecrosis of the talus, osteonecrosis of the lunate, osteonecrosis of the scaphoid, and others.
Drug Type
- Branded
- Generic
On the basis of drug type, the market is segmented into branded and generic.
Prescription
- Over the Counter Drugs
- Prescribed Drugs
On the basis of prescription, the market is segmented into over the counter drugs and prescribed drugs.
Gender
- Male
- Female
On the basis of gender, the market is segmented into male and female.
Age
- Children
- Adult
- Geriatric
On the basis of age, the market is segmented into children, adult, and geriatric.
End User
- Hospitals
- Speciality Clinics
- Orthopedic Clinics
- Ambulatory Centers
- Others
On the basis of end user, the market is segmented into hospitals, specialty clinics, orthopedic clinics, ambulatory centers, and others.
Distribution Channel
- Direct Tender
- Retail Sales
On the basis of distribution channel, the market is segmented into direct tender and retail sales.
U.S. Osteonecrosis Market Analysis/Insights
The U.S. osteonecrosis market is categorized into ten notable segments based on disease type, type, stages, location, drug type, prescription, gender, age, end user, and distribution channel.
The countries covered in this market report U.S.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of U.S. brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and U.S. Osteonecrosis Market Share Analysis
The U.S. osteonecrosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the U.S. osteonecrosis market.
Some of the major market players operating in the U.S. osteonecrosis market are Sciegen Pharmaceuticals, Almatica Pharma, Dr. Reddy's Laboratories Ltd., Bayer AG, Pfizer Inc., Haleon Group of Companies, Zimmer Biomet, Stryker, Teva Pharmaceuticals USA, Inc. (Subsidiary of Teva Pharmaceutical Industries Ltd.), and Arthrex, Inc. among others.
SKU-